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Background: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and
efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease.
Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its
development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic
anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to
assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in
African children <5 years of age with uncomplicated malaria.
Methods: This case–control study was performed in the context of a larger multicentre randomized clinical trial
comparing safety and efficacy of four different ACT in children with uncomplicated malaria. Children, who after
treatment experienced a haemoglobin drop ≥2 g/dl (cases) within the first four days (days 0, 1, 2, and 3), were
compared with those without an Hb drop (controls). Cases and controls were matched for study site, sex, age and
baseline haemoglobin measurements. Data were analysed using a conditional logistic regression model.
Results: G6PD deficiency prevalence, homo- or hemizygous, was 8.5% (10/117) in cases and 6.8% (16/234) in
controls (p = 0.56). The risk of a Hb drop ≥2 g/dl was not associated with either G6PD deficiency (adjusted odds
ratio (AOR): 0.81; p = 0.76) or CDA treatment (AOR: 1.28; p = 0.37) alone. However, patients having both risk factors
tended to have higher odds (AOR: 11.13; p = 0.25) of experiencing a Hb drop ≥2 g/dl within the first four days after
treatment, however this finding was not statistically significant, mainly because G6PD deficient patients treated with
CDA were very few. In non-G6PD deficient individuals, the proportion of cases was similar between treatment
groups while in G6PD-deficient individuals, haemolytic anaemia occurred more frequently in children treated with
CDA (56%) than in those treated with other ACT (29%), though the difference was not significant (p = 0.49).
Conclusion: The use of CDA for treating uncomplicated malaria may increase the risk of haemolytic anaemia in
G6PD-deficient children.
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Chlorproguanil–dapsone (CD) is a fixed-dose anti-folate
combination that was developed by a public-private part-
nership for the treatment of Plasmodium falciparum un-
complicated malaria [1]. CD received approval from the
UK Regulatory Agency in July 2003 for the treatment of
uncomplicated falciparum malaria in non-pregnant
adults. Data from the phase III clinical programme con-
ducted in children in sub-Saharan Africa showed that
CD achieved significantly higher cure rates compared to
sulphadoxine-pyrimethamine (SP) and was well tolerated
[2]. Importantly, CD was active against SP-resistant para-
sites in Africa [3,4]. However, and following the signifi-
cant reduction of haemoglobin (Hb) observed in patients
with glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency after treatment with CD and artesunate (CDA) in
two phase III trials [1,5], clinical research on this product
was stopped and all CD doses already on the market
withdrawn [6].
Dapsone is metabolized in a hydroxylamine metabolite
that is susceptible to trigger oxidation damages in red
blood cells, leading, if not thwarted by a protection
mechanism, to haemolytic anaemia [7]. This is a concern
in G6PD-deficient individuals. This genetic polymorph-
ism is particularly prevalent in malaria-endemic areas,
and affects about 400 million people worldwide [8].
G6PD, a cytoplasmic enzyme expressed in all cells, cat-
alyses the first step of the pentose phosphate pathway
and plays an essential role in protecting red blood cells
from oxidative stress [9]. The G6PD gene is located on
the chromosome X, meaning that it mainly affects males.
The G6PD gene is highly polymorphic; more than 400
allelic variants have been described, including 34 differ-
ent mutations with an allelic frequency higher than 1%
[10,11]. According to biochemical characteristics and to
genome mutations, G6PD gene is considered as tri-allelic
in sub-Saharan Africa: (1) G6PD type B, the most common
allelic form, coupled with a normal enzymatic activity, (2)
G6PD type A with one point mutation A376G (Asn !
Asp) and 85% activity and (3) G6PD type A- with two
point mutations A376G and G202A (Val! Met) and 12%
activity [12]. In some cases, the second mutation is either
G680T or T968G. Other mutations have been occasionally
reported, such as A- Betica or A- Sierra Leone [13]. In
tropical Africa, G6PD type A- (class III) represents 90% of
all G6PD deficiencies.
In a G6PD-deficient individual, oxidative stress can ser-
iously damage red blood cells (reactive oxygen species gen-
eration, partial Hb denaturation, Heinz bodies production,
membrane function alteration), resulting in acute haem-
olysis. When acute haemolysis is triggered by a treatment
such as CD, Hb drop can be of about 2 g/dl within one or
two days after treatment administration [14]. Unlike
G6PD Mediterranean, a more severe deficiency in whichhaemolysis continues until well after the administration of
drug is stopped, the haemolytic anaemia caused by G6PD
A- is self-limited because only the older red blood cells are
destroyed [9]. Epidemiological and in vitro studies sug-
gested that G6PD deficiency could confer a protection
against P. falciparum infection by inhibiting erythrocyte
invasion or intracellular development of the malaria para-
site [12]. Given the current recommendation to use arte-
misinin-based combination therapy (ACT), in which an
artemisinin derivative is combined with another anti-
malarial drug, CDA was developed as a low-cost, simple,
fixed-dose ACT for use in Africa [1]. However, results of a
recent multicentre trial comparing CDA to CD alone
showed that, despite its better efficacy, CDA haemolytic
risk in G6PD-deficient patients did not allow further use
of this treatment [1]. Nevertheless, a multicentre trial in-
cluding non-co-formulated CDA as a study treatment had
already started and a few hundred children had already
been included before the decision to stop CDA develop-
ment was taken. The objective of the study was to assess
whether CDA treatment and G6PD deficiency constitute
risk factors for a post-treatment Hb drop in African chil-
dren <5 years of age with uncomplicated malaria.
Methods
Study site and population
This study was part of a large multicentre trial (seven
African countries, 12 sites) testing the safety and efficacy
of four ACT for uncomplicated malaria in children, namely
dihydroartemisinin-piperaquine (DHAPQ), amodiaquine-
artesunate (AQ + AS), artemether-lumefantrine (AL), and
CDA (Trial Registration NCT00393679 [15]). Details of the
study methods are described elsewhere [16].
Briefly, CDA was compared with DHAPQ and AL in
Rwanda (Rukara, Mashesha) and in Uganda (Jinja, Tororo)
and with DHAPQ and AQ + AS in Uganda (Mbarara) and
Mozambique (Manhiça). Rwandan samples were not
included in the series as they were not available at the time
of the analysis. Children aged 12–59 months old with un-
complicated malaria were randomly allocated to one of
the three study arms if they fulfilled the following inclu-
sion criteria: body weight >5 kg; P. falciparum mono-
infection with density between 2,000 and 200,000/μl;
fever (axillary temperature ≥37.5°C) or history of fever
in the last 24 hours, and Hb ≥7 g/dl. Exclusion criteria
were: participation within the last month in any other
investigational drug study; known hypersensitivity to at
least one of the study drugs; severe malaria [17] or other
danger signs; severe malnutrition or any other illness or
condition (cardiac, renal, hepatic diseases) that would
interfere with the study results, including known G6PD
deficiency; contra-indication to receive the trial drugs;
or ongoing prophylaxis with drugs having anti-malarial
activity. Eligible patients were allocated one of the four
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by country, with each treatment allocation concealed in
opaque sealed envelopes that were opened only after
patient’s enrolment.
Intervention
Treatment was administered under direct supervision dur-
ing three consecutive days and according to the patient’s
body weight. CD was orally administered at a dose of
2.0 mg/kg of chlorproguanil and 2.5 mg/kg of dapsone once
a day during three days, using commercial LapdapW paedi-
atric tablets containing each 15 mg of chlorproguanil and
18.75 mg of dapsone. ArsumaxW tablets (Guilin Pharma-
ceutical Co. Ltd. Guangxi for Sanofi-Synthelabo, Gentilly,
France) containing 50 mg of artesunate were given at the
dosage of 4 mg/kg/day during three days. The other formu-
lations of ACT were administered according to the manu-
facturers’ instructions [16].
Follow-up
All children were kept at the health facility during the
three-day dosing period. The mother/guardian was asked
to return with the child for scheduled visits on days 3, 7,
14, 21 and 28 post-treatment, or if any symptoms oc-
curred between scheduled visits. Capillary or venous
blood was taken at each visit. The follow-up description
can be found in the main study methods [16].
Parasite density and hb measurements
Thick and thin blood films were prepared, dried and
Giemsa stained; parasite density was estimated by count-
ing the number of asexual parasites in 200 white blood
cells (WBC), assuming a standard WBC count of 8,000/
μl. Hb was measured using HemoCueW device at day 0,
before treatment, and using an haematology analyser
(ABX Pentra 60 in Mbarara & Sysmex KX-21N in
Manhiça, Jinja and Tororo) at days 1, 2, 3, 7, and 28.
Three blood spots were collected on filter paper (What-
man Grade 3) at enrolment and at each visit from day 7
onwards. Each filter paper was dried and individually
stored in a plastic bag containing silica gel. All filter
papers were subsequently transferred to the Institute of
Tropical Medicine (Antwerp, Belgium) for genotyping.
G6PD type A- detection
DNA was extracted from dried blood spot on filter paper
with the Chelex method [18]. Considering that type A- is
the most common allele in sub-Saharan Africa, the presence
of the G202A mutation was assessed by polymerase chain
reaction (PCR)-restriction fragment length polymorphisms
(RFLP) [19,20]. Sequences containing mutation site were
amplified by PCR using following primers: CAG-CCA-
CTT-CTA-ACC-ACA-CAC-CT (forward) and CCG-AAG-
TTG-GCC-ATG-CTG-GG (reverse) [20]. PCR conditionswere: MgCl2 1.5 mM, dNTP 0.6 mM, each primer 0.2 μM,
Taq polymerase 0.02U/μl, DNA 1 μl, buffer 1x and Milli-Q
water. Cycler programme steps were: primary denaturation
5’ at 95°C, denaturation 1’ at 95°C, annealing 45” at 64°C,
extension 1’ at 72°C, 34 cycles, and final extension 5’ at 72°
C. The 202 mutation was detected with the NlaIII restric-
tion enzyme that cleaves DNA only if mutation is present.
RFLP conditions were: NlaIII 0.08U/μl, BSA 1x, buffer,
Milli-Q water and 5 μl of the PCR product. After eight
hours of incubation at 37°C, enzyme was inactivated 20’ at
65°C. Digested DNA samples were run in a 2% agarose gel
by electrophoresis in Tris-Acetate-EDTA (TAE), marked
with ethidium bromide and revealed with UV. Results were
interpreted as followed: one band (338 bp) corresponds to B
or A genotype, two bands (215 bp, 123 bp) correspond to
A- genotype, and three bands (338 bp, 215 bp, 123 bp) cor-
respond to heterozygotes (BA- or AA- genotype).
Data analysis
A matched case control approach was used. Children
with a Hb drop ≥2 g/dl within three days post-treatment
were considered as cases and all others as controls. As
the number of participants with a Hb drop was low, two
matched controls were selected for each case in order to
increase the power of the analysis. Controls were
matched for study site, sex, age (<10 months difference)
and Hb at baseline (<1 g/dl difference). Proportions
were compared using chi-square or Fisher exact tests
and continuous variables were compared using Student’s
t test. The geometric mean of the parasite density was
used as threshold between “high” and “low” parasitaemia.
Mild anaemia was defined as Hb <11 g/dl. Data were
analysed using NCSS software (Number Cruncher Statis-
tical Systems 2004/PASS 2005, Kaysville, UT, USA). A
conditional logistic regression model was built using
STATA version 9 (Stata Corporation, College Station,
TX). Multi-colinearity was checked and no variance in-
flation factor was greater than 10. Stepwise multivariate
analyses were performed, and all possible interactions up
to order 2 were tested, checking at each step how effects
and likelihood were modified (likelihood ratio test and
Akaiké information criterion, AIC). Adjusted odds ratios
(AORs) and standard errors (SE) were calculated taking
into account the interaction term. A p-value <0.05 was
considered as significant; all p-values are 2-sided and
reported confidence intervals (CI) are 95%CI.
Results
Post-treatment haemolysis
Hb data were not available for at least one of the first
four days for 127 patients and 107 Rwandan samples
were not available. Among the remaining 571 patients,
Hb dropped by ≥2 g/dl in 117 (20.5%). Mean Hb de-
crease, compared to day 0, was 0.57 g/dl (CI: 0.47-0.60)
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(CI: 0.43-0.59) at day 3. In most cases (43%, 50/117), the
≥2 g/dl drop occurred at day 2. Haematological recovery
was observed commencing at day 3 onwards, with a
mean Hb of 11 g/dl (CI:10.9-11.1) at day 28. In one child
Hb dropped from 6.5 g/dl at day 0 to 3.3 g/dl at day 7,
requiring a blood transfusion. The child was G6PD het-
erozygote and treated with CDA.
The lowest percentage of patients with a Hb ≥2 g/dl
drop was observed in Tororo in Uganda (Table 1,
p = 0.015), which also showed the lowest mean age
(26.6 months vs 33.8, 32.7 and 31.1 in Manhiça, Mbarara
and Jinja, respectively, p = 0.0001) The Hb ≥2 g/dl drop
was more frequent in children under 28 months
(p = 0.026) with a high parasite density (p = 0.034), and
without mild anaemia (p< 0.001). Percentage of patients
whose Hb dropped by ≥2 g/dl did not differ between
treatment groups (Table 1).
G6PD deficiency
Patients’ recruitment started in the different sites between
July and October 2007 and CDA allocation was stopped inTable 1 Percentage of patients whose Hb dropped by
≥2 g/dl (cases), by study site and risk factors
ΔHb≥ 2 g/dl (%) p-value*
Site
Mozambique Manhiça 23.4 (49/209) 0.015
Uganda Mbarara 23.8 (41/172)
Uganda Tororo 8.6 (8/93)
Uganda Jinja 19.6 (19/97)
Sex
Boys 21.1 (64/303) 0.691
Girls 19.8 (53/268)
Age, months
12–27 35.3 (38/248) 0.026
28–43 25.1 (51/203)
44–60 23.3 (28/120)
Mild anaemia (Hb<11 g/dl)
Yes 13.9 (63/452) <0.001
No 45.4 (54/119)
Parasite density
Low (<29623 μl-1) 15.5 (39/251) 0.034
High (>29623 μl-1) 24.4 (78/320)
Treatment
CDA 22.0 (42/191) 0.312
AL 13.1 (8/61)
DHAPQ 18.9 (36/190)
AQ + AS 24.0 (31/129)
CDA = chlorproguanil-daspone + artesunate. AL = artemether-lumefantrine.
DHAPQ = dihydroartemisinin-piperaquine. AQ + AS = amodiaquine-artesunate.
*Chi-square test.February 2008. At the time the CDA arm was stopped,
805 patients had already been included in the sites evaluat-
ing CDA. One hundred and seventeen cases could be
matched to 234 controls using a ratio 1:2 (Table 2). G6PD
deficiency (homozygous A-) was found in 8.5% (10/117) of
cases and in 6.8% (16/234) of controls (p= 0.56). As
expected, homozygous girls represented only a small pro-
portion (7.7%, 2/26) of deficient subjects and were absent
from the control group. Nearly one in four girls carried
the A- mutation as heterozygous (24%, 40/165). In boys,
13% (24/186) were hemizygous, with no difference be-
tween cases and controls. The proportion of deficient A-
subjects varied across the study sites: 3.3% (CI: 0.9-8.3) in
Mbarara, 8.3%; (CI: 1.0-27.0) in Tororo, 14.8% (CI: 6.6-
27.1) in Jinja, Uganda and 7.8% (CI: 4.1-13.3) in Manhiça,
Mozambique. In non-G6PD deficient individuals, the pro-
portion of cases was similar between treatment groups
(AQ+AS: 35%, AL: 26%, CDA: 35%, DHAPQ: 31%,
p = 0.75). However, in G6PD-deficient individuals, haemo-
lytic anaemia occurred more frequently in children treated
with CDA (5/9) than in those treated with other ACT
though the difference was not significant (Figure 1,
p = 0.49). The five cases in the 17 deficient children treated
with another ACT were distributed as follows: 2/4 in AQ
+ AS, 1/1 in AL and 2/12 in DHAPQ.
Effects of G6PD deficiency and CDA on post-treatment
haemolysis risk
In assessing the effect of G6PD deficiency and CDA
treatment on a Hb ≥2 g/dl drop, all plausible interactions
were considered but only the interaction CDA*G6PD de-
ficiency was retained because, even if non-significant,
effects were modified when the interaction was deleted.
This indicates that, in terms of Hb decrease, CDA treat-
ment effect was different between G6PD-deficient and
normal children. The final conditional logistic regression
model (Table 3) included Hb at baseline, log of parasite
density, G6PD deficiency, CDA and the CDA*G6PDTable 2 Comparison of G6PD status between cases and
controls matched for study site, sex, age and Hb at
baseline (%)
Cases ΔHb≥ 2 g/dl Controls ΔHb< 2 g/dl
(n = 117) (n = 234)
Deficient A-*
Homozygous girls 2 (1.7) 0 (0.0)
Hemizygous boys 8 (6.8) 16 (6.8)
Heterozygote A-
Girls 10 (8.5) 30 (12.8)
Normal
Boys 54 (46.1) 108 (46.1)
Girls 43 (36.7) 80 (34.2)
* defined as a detection of mutation 202 in amplified DNA.
Figure 1 Proportion of children with a Hb drop ≥2 g/dl (cases)
across G6PD status and treatment groups. CDA =
chlorproguanil-dapsone + artesunate. Other ACT = artemether-
lumefantrine, dihydroartemisinin-piperaquine, amodiaquine-
artesunate.
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drop by ≥2 g/dl. G6PD deficient individuals treated with
CDA had higher odds of experiencing a Hb drop of
≥2 g/dl than non-G6PD deficient individuals treated with
another ACT (OR= 11.13, CI: 0.63-197), though it did
not reach statistical significance (Table 3).
Discussion
Neither CDA treatment nor G6PD alone were risk factors
for post-treatment haemolysis though children with both
factors seemed to be more likely to experience, within the
first four days after starting the treatment, a Hb drop of
≥2 g/dl. These results are consistent with other reports on
CD. In a multicentre randomized trial that included 1,850
children with uncomplicated falciparum malaria, G6PD-
deficient malaria patients treated with CD had a Hb
drop at day 7 that was not observed in G6PD-normal
patients [2]. In Rwanda [21], G6PD-deficient subjects
treated with CDA had a significantly higher risk for
haemolytic anaemia than those treated with amodiaquine
and artesunate [22]. In the phase III trial comparing CDATable 3 Uni- and multivariate determinants of haemolytic ana
clinical malaria, using conditional logistic regression
Variable OR (95%CI)
Baseline Hb in g/dl 7.27 (3.63–14.54)
Log parasite density/μl 1.29 (1.06–1.59)
A- G6PD deficiency (vs. G6PD normal) 1.32 (0.54–3.23)
CDA (vs. other ACT†) 1.25 (0.79–1.99)
A- G6PD and CDA (vs. G6PD normal and other ACT)*
OR = Odds Ratio. AOR = Adjusted Odds Ratio. CI = Confidence Interval.
† artemether-lumefantrine, dihydroartemisinin-piperaquine, or amodiaquine-artesun
} AOR value when the other co-variable in the interaction term (CDA or G6PD) equa
* AOR, 95% CI and p-value were computed using the Wald χ² statistic.with artemether-lumefantrine [6,5], both CDA and G6PD
deficiency were independently associated with the occur-
rence of a Hb composite safety endpoint comprising the
occurrence of a Hb decrease of≥ 40 g/L or ≥40% vs base-
line or Hb <50 g/L or blood transfusion. Occurrence of
this Hb composite safety endpoint in G6PD deficient
patients was 35% with CDA and 0% with AL. G6PD defi-
ciency was also reported by Tiono et al. [1] as the main
significant risk factor for a Hb safety endpoint in patients
treated with CDA or CD alone. Though using different
methods and studying different age populations, all afore-
mentioned studies illustrated that the impact of dapsone
(CDA or CD) on Hb level occurred mainly in G6PD defi-
cient patients (i.e. the effect of the interaction between the
CD(A) treatment and G6PD deficiency).
Observations on heterozygotes are difficult to interpret
because they have two red blood cells populations and
their proportion varies between individuals [14]. Hetero-
zygotes were considered as G6PD-normal patients on
the assumption that type A-, a moderate G6PD defi-
ciency (of class III), could barely trigger clinical manifes-
tations if only a part of red blood cells was affected.
Nevertheless, heterozygotes having large proportion of
deficient red blood cells may have been misclassified as
normal.
The biomolecular approach used is appropriate when
G6PD-deficiency type is known. In sub-Saharan Africa,
G6PD type A- is extremely common but can be caused by
several mutations. Genotypes A- with different mutations
than that tested in this study (G202A) have been reported.
It is estimated that the A376G-G680T and A376G-T968G
genotypes represent less than 5% of type A- deficiencies,
though in Senegal they are more frequent than the usual
A376G-G202A [23]. There are no data on the genotypes
A- related mutations in Mozambique and Uganda so that
some patients in these sites may have been misclassified in
terms of G6PD status. Matching allowed controlling for
site, sex and age in the analysis. However, as Hb at baseline
was not completely matched, it was kept in the model as
an independent predictor. Haemoglobin drop ≥2 g/dl
criterion in the first days after treatment was determinedemia in 12–59 months children (n = 351) treated for a
p-value AOR (95%CI) p-value
<0.001 7.05 (3.6–13.88) <0.001
0.012 1.17 (0.93–1.47) 0.17
0.54 0.81} (0.21–3.08) 0.76
0.34 1.28} (0.74–2.22) 0.37
11.13 (0.63–197) 0.25
ate.
ls 0.
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lowest haemoglobin value is usually observed at day 3
after treatment [2,24]. The composite Hb safety enpoint
would not have been applicable in the present study as
only 10 children would have met this criterion (taking
observations from day 0 to day 7). In this sample, mean
Hb decrease from baseline did not exceed 1 g/dl at any
day. Therefore the ≥2 g/dl criterion was judged suffi-
cient to select the “severe” post-treatment haemolysis.
Body temperature was excluded from the model because
it was judged less reliable. The choice of the reported
analyses was based on the assumption that in G6PD de-
ficient children, the proportion of cases would be higher
in children treated with CDA than in children treated
with other ACT. Sample sizes of nine deficient children
in CDA treatment group and 17 deficient children in
other treatment groups had a 22% power to detect a dif-
ference of 26% using the two-sided Fisher’s exact test.
With such sample sizes, the difference should be at least
57% to reach a power of 80%. It should be noticed that
only 7% of children were G6PD deficient (less than
reported in [25,26]); the size of the effect (5/9-5/17)
remains high even if not statistically significant.
The available information indicates that CDA in
G6PD-deficient patients is associated with a substantial
risk of haematological toxicity, due to an oxidant metab-
olite of dapsone causing haemolytic damages in these
patients. Assuming the CDA development would have
continued, it would have implied that, before any treat-
ment, patients would have to be tested for G6PD defi-
ciency, e.g. with the cheap and fast Beutler’s fluorescent
test [27] judged nearly as good as the biomolecular
(PCR/RFLP) method [28], a difficult measure to imple-
ment in busy outpatient clinics. In addition, a recent sta-
bility study observed a degradant in CDA which has the
potential to limit the shelf-life of the product [29], ren-
dering the deployment of this treatment even more diffi-
cult. When considering also the potential for drug
resistance, CDA may not successfully treat patients car-
rying parasites with the Pfdhfr I164L mutation, mainly
found in Asia while this particular mutation seems rare
in sub-Saharan Africa [30,31]. For the aforementioned
reasons, stopping the development of CDA appears as
the only possible decision.
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